Management

James Powers Chairman and CEO
James Powers
Chairman and CEO

James C. Powers serves as CEO and chairman of the Board of Directors for HemoShear Therapeutics.   Prior to joining HemoShear in 2009, Mr. Powers spent 18 years with PRA International where he was a member of the executive team that grew the company into a global clinical trials management organization and took the company public.  After retiring from PRA, he was an advisor to the Coulter Translational Research Partnership in the Biomedical Engineering Department at the University of Virginia where he met HemoShear’s co-founders.  In 2014, Mr. Powers was selected to join PharmaVoice’s Top 100 Most Inspiring leaders in healthcare.  He currently serves on the board of Virginia BIO and is chairman of the Virginia BIO Foundation.  Mr. Powers received a B.S. in administration and management science from Carnegie-Mellon University. 

Brian Wamhoff, PhD Head of Innovation
Brian Wamhoff, PhD
Co-founder and Head of Innovation

Dr. Wamhoff serves as HemoShear Therapeutics' Head of Innovation and is a company founder.  He is responsible for development and management of strategic team initiatives to ensure a robust pipeline of disease models to advance our drug discovery platform and early stage therapeutic programs.  Dr. Wamhoff has led teams to oversee the successful development of human vascular and liver disease models, as well as ongoing development of a tumor microenvironment system.  These advancements have been built in part by his role in securing significant NIH Small Business Innovation Research funding from five different NIH institutes. Additional activities include scientific publication strategy and activities, thought leader development and engagement activities, and intellectual property and patent strategy. Dr. Wamhoff, former Associate Professor at the University of Virginia, has co-founded multiple medical device and therapeutics companies.  He obtained a B.S. in biology with a minor in business administration from Rhodes College, where he was the 2011 Distinguished Alumnus; he received his Ph.D. in medical physiology from the University of Missouri.

John Reardon, PhD Head of R&D
John Reardon, PhD
Research & Development

John E. Reardon is the acting Head of Research and Development for HemoShear Therapeutics.  Prior to joining HemoShear in 2016, Dr. Reardon was the Chief Scientific Officer at Cardioxyl Pharmaceuticals, Inc where he successfully led development of a heart failure therapeutic in to Phase II, which was acquired by Bristol-Meyers Squibb in 2015 in a potential $2B deal.  Before joining Cardioxyl, Dr. Reardon was Executive Vice President and Chief Scientific Officer at Integrated Oncology Solutions, Inc. from 2007 – 2009. Dr. Reardon spent 19 years at GlaxoSmithKline PLC and its predecessor companies where he held a variety of leadership positions.  As Senior Vice President of Discovery Research Biology at GlaxoSmithKline he oversaw the biological science supporting lead discovery activities across all the therapeutic areas in the international GSK R&D organization.  Dr. Reardon received a B.A. from Willamette University, Oregon and a PhD degree in Chemistry from The Ohio State University, Ohio. He was an NIH post-doctoral fellow in the laboratory of Dr. Robert Abeles at Brandeis University before joining Burroughs-Wellcome Co. in 1986. 

 

Aric Holsinger, CPA CFO
Aric Holsinger, CPA
Chief Financial Officer

Aric Holsinger serves as HemoShear Therapeutics’ Chief Financial Officer and is responsible for the financial, tax, and accounting activities of the company. Prior to joining HemoShear, Mr. Holsinger was Chief Financial Officer of Cricket Media, an education technology company, for 7 years and led the company through a public offering and ultimately returned to private status. Previously Mr. Holsinger held CFO and VP Finance positions with MCT, a cellular telecommunications provider in Russia and Central Asia; the Baltimore Stallions, a franchise in the Canadian Football League; and the Baltimore Orioles.  Mr. Holsinger began his career with Arthur Andersen in Washington, DC and received his B.S. degree in accounting and management information systems from the University of Virginia.

Board of Directors

James Powers Chairman and CEO
James Powers
Chairman and CEO

James C. Powers serves as CEO and chairman of the Board of Directors for HemoShear Therapeutics.   Prior to joining HemoShear in 2009, Mr. Powers spent 18 years with PRA International where he was a member of the executive team that grew the company into a global clinical trials management organization and took the company public.  After retiring from PRA, he was an advisor to the Coulter Translational Research Partnership in the Biomedical Engineering Department at the University of Virginia where he met HemoShear’s co-founders.  In 2014, Mr. Powers was selected to join PharmaVoice’s Top 100 Most Inspiring leaders in healthcare.  He currently serves on the board of Virginia BIO and is chairman of the Virginia BIO Foundation.  Mr. Powers received a B.S. in administration and management science from Carnegie-Mellon University. 

John Brooks, III Board Member
John Brooks, III
Board Member

John L. Brooks, III, is the CEO of Arete Worldwide, LLC in Boston. He was previously the President and CEO of the Joslin Diabetes Center. He serves on the boards of Pathfinder Cell Therapy, Noxilizer, Ammonett Pharma, Longwood Energy Collaborative, Reflectance Medical, Inc., Suffolk University and Thermalin Diabetes. He was a founding partner of Prism Ventureworks. Prism has raised more than $1.25 billion and is based in Needham, MA. Mr. Brooks was formerly a general manager at Pfizer/Valleylab in Boulder, CO, where he developed and executed a minimally invasive surgery and emerging businesses strategy. Prior to Valleylab, he led the growth of a rapidly evolving vascular access medical device business at Pfizer/Strato Medical. Mr. Brooks has co-founded three paradigm-shifting life sciences companies: Songbird Hearing, Locus Pharmaceuticals and Insulet (PODD). He is a biotechnology advisory board member for Draper Labs. In addition, Mr. Brooks is a member of M2D2, an early-stage medical technology accelerator and a board member of the Massachusetts Technology Transfer Center (MTTC) advisory boards. He holds an MS in business and a BBA cum laude from the University of Massachusetts at Amherst. He is a certified public accountant and a certified financial planner.

H. Thomas Watkins Board Member
H. Thomas Watkins
Board Member

H. Thomas Watkins is former Director, President, and CEO of Human Genome Sciences (HGS) from 2004 until HGS was acquired by GlaxoSmithKline in 2012. During his tenure, HGS successfully developed and brought Benlysta to market in 2011, the first new lupus drug to be introduced in 50 years. Prior to HGS, Mr. Watkins spent over 20 years in senior roles at Abbott and its affiliates in the U.S. and Asia. He was President of TAP Pharmaceutical Products, Inc., which was jointly owned by Abbott and Takeda Pharmaceutical Company, Inc., where he led the growth of TAP from approximately $2 billion to over $4 billion in annual revenue. Previously, Mr. Watkins was a consultant with McKinsey and Company and Arthur Andersen. He is former Chairman of the Biotechnology Industry Organization (BIO) and continues to serve on its board. He is currently Chairman of the board of directors of Vanda Pharmaceuticals, Inc., and Vice Rector of the Board of Visitors of The College of William and Mary. Mr. Watkins received a B.B.A. in accounting from the College of William and Mary and his M.B.A. from the University of Chicago Graduate School of Business, now the Booth School of Business.

Robert J. Gould, PhD Board Member
Robert J. Gould, PhD
Board Member


Robert J. Gould, Ph.D. is former President, Chief Executive Officer and current board member of Epizyme, a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients. He has held this position since March 2010, serving on the board of Epizyme from 2008 - 2010. Prior to joining Epizyme in March 2010, Dr. Gould was Director of Novel Therapeutics from 2007 - 2010 at The Broad Institute of MIT and Harvard. Dr. Gould spent 23 years at Merck & Co., Inc., a healthcare company, where he held a variety of leadership positions during his tenure there. As Vice President, Basic Research, he oversaw drug discovery activities for seven therapeutic areas, as well as Merck’s centralized high throughput screening facility. In addition, he spent three years as Vice President, Licensing and External Research. Dr. Gould received a B.A. in chemistry from Spring Arbor College, Michigan and a Ph.D. in biochemistry from The University of Iowa, Iowa. He also conducted post-doctoral studies in  neuropharmacology at The Johns Hopkins University before joining Merck & Co., in 1981.

Mehmood Khan, MD Board Member
Mehmood Khan, MD
Board Member

Mehmood Khan, MD, is the Vice Chairman of PepsiCo, Inc., where he is responsible for leading all aspects of the company’s research and development and product and equipment strategy. He provides global leadership and support to division research and development groups in the areas of enterprise research planning, R&D portfolio management, next generation technologies, nutritional standards, food safety and regulation and quality assurance. Prior to joining PepsiCo in 2007, Dr. Khan served as president of Takeda Global Research & Development Center, Inc. (TGRD). Dr. Khan has also served as consultant physician in Endocrinology and Director of the Diabetes, Endocrine and Nutrition Clinical Trials Unit in the Division of Endocrinology at the Mayo Clinic in Rochester, Minn.

Dr. Khan earned his MD from the University of Liverpool Medical School, England, and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a member of the Royal College of Physicians, London and a fellow of the American College of Endocrinology.

Reginald Woods Board Member
Reginald Woods
Board Member

Reginald F. Woods was CEO of Butler International where he led a successful corporate turnaround that became the subject of three Harvard Business School case studies.  The Butler companies generated significant earnings expansion through organic growth and acquisitions in their respective industries.  Butler International was listed on the NYSE and was later acquired by a financial buyer at an attractive valuation. Mr. Woods then co-founded a merger and acquisition consulting practice specializing in the insurance industry. He is a founding Director of HemoShear Therapeutics, LLC, a founding Director and Chairman of Dynamic Literacy, LLC, and a Director of Scitent, Inc. He is on the Advisory Board of the University of Virginia Heart and Vascular Center, was co-founder of the Keswick Community Foundation, and has served on the board and executive committee of Habitat for Humanity of Greater Charlottesville. He earned B.S. and M.S. degrees in engineering and an M.B.A. from Cornell University.

W. M. Thompson, Jr. General Counsel
W. M. Thompson, Jr.
Board Member and General Counsel

W. McIlwaine (Mac) Thompson, Jr. is of counsel to the law firm of Woods Rogers PLC and specializes in representing companies in many diverse fields including biotechnology, information technology and oil and gas exploration. Mr. Thompson is secretary of Insmed Incorporated, a publicly traded biotechnology company, and is a member of the boards of Mestena Inc., an oil- and gas-exploration company, and Foundation Energy Management, LLC, which acquires oil- and gas-producing properties. He is a member of the investment advisory board of Tall Oaks Capital, a venture capital fund based in Charlottesville, and has represented many biotechnology companies in the Charlottesville area. He is also a member of the advisory board for the University of Virginia’s Heart and Vascular Center and general counsel to, and immediate past chair of, the board of the U.Va. Curry School of Education Foundation. Mr. Thompson graduated from Yale College in 1969 and the U.Va. Law School in 1972.

Advisors

PROPIONIC ACIDEMIA AND METHYLMALONIC ACIDEMIA CLINICAL ADVISORY BOARD

Marshall Summar, MD, Children's National Medical Center, Chief Genetics and Metabolism; Margaret O’Malley Professor of Genetic Medicine; National Organization of Rare Diseases (NORD, Chairman of the Board)

Moeen Alsayed, MD, King Faisal Specialist Hospital (KSA), Chairman of Medical Genetics

Mattias Baumgartner, MD, University of Zurich, Head of the Division of Metabolic Diseases at the Children's Hospital Zurich

Greg Enns, MD, Stanford University, Professor of Pediatrics (Genetics) at the Lucile Salter Packard Children's Hospital

Nicola Longo, MD, Ph.D., University of Utah, Chief of the Division of Medical Genetics; Professor of Pediatrics at Primary Children’s Medical Center

 

NASH ADVISOR

Arun Sanyal, MD,  NAFLD/NASH Consultant: Professor and Chair, Division of Gastroenterology, Hepatology and Nutrition, VCU; Chairman, NIH NASH Research Network.

 

R&D ADVISORS

Tony Bower, Ph.D., Reimbursement Consultant: President, BRG LLC; VP Global Pricing, Reimbursement and Health Economics, Synageva BioPharma; Head of Pricing, Amgen; Senior Economist, RAND.

John Dillberger, DVM, Ph.D. Diplomate ACVP and ABT, Fellow IATP. Toxicology Consultant: J Dillberger LLC; Charles River Labs; Triangle Pharmaceuticals; Glaxo Wellcome

Mark Hayes, Ph.D., Regulatory Affairs Consultant: HayesWays LLC; SVP Regulatory Affairs, Synageva BioPharma; Genzyme; FDA

Donald Hertzog, Ph.D., Chemistry Consultant: Don Hertzog Consulting LLC; VP Lead Identification, Abide Therapeutics; RTP Site Head, Department of Medicinal Chemistry, Molecular Discovery Research, GSK

John LaMattina, Ph.D., Business Strategy Consultant: President, Pfizer R&D; Board Director, PureTech Ventures

Sandra Rojas-Caro, M.D., Medical Advisor: Yagan Consulting LLC; CMO Aglea Pharmaceuticals; VP Rare Metabolic Diseases, Alexion; Head of Clinical R&D, Synageva BioPharma